Trial · NCT04106180
SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC
NCT04106180, Phase 2, Unknown, Fudan University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC. Trials, record NCT04106180. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04106180
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC
- NCT number
- NCT04106180
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 63 participants, estimated
- Lead sponsor
- Fudan University
- Conditions
- NSCLC Stage IV
- Interventions
- GM-CSF, Sintilimab, SBRT
- First posted
- 2019-09-26
- Last updated
- 2019-09-26
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Objective Response Rate | At least 6 weeks after start of treatment | ORR was defined as the proportion of participants with partial response (PR) or complete response (CR) to treatment as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. |
| Secondary | Percentage of Participants With Adverse Events | Two years | Treatment-related adverse events were assessed and graded according to CTCAE v. 5.0. |
| Secondary | Objective Response Rate (ORR) in Non-irradiated Lesion | At least 6 weeks after start of treatment | Objective Response Rate (ORR) in Non-irradiated Lesion was defined as the proportion of patients with at least 30% reduction from baseline in the longest diameter of any of non-irradiated target lesions defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 at any time-point from the date of treatment initiation to the date of last follow-up. |
| Secondary | Overall Survival | Two years | OS was defined as the time from the date of enrollment until death by any cause. Participants still alive at the time of data analysis were censored at the date of last follow-up. |
| Secondary | Progression Free Survival | Two years | PFS was measured from the date of enrollment to the date of disease progression as defined by Response Evaluation Criteria in Solid Tumor (RECIST) Version 1.1 or death due to any cause, whichever occurred first. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 34526044 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04106180
GET https://conductscience.org/api/trials/v1/NCT04106180/registered